Department of Information, Tangdu Hospital, The Fourth Military Medical University, Xi'an, Shannxi 710032, P.R. China.
Oncol Rep. 2013 Nov;30(5):2179-86. doi: 10.3892/or.2013.2679. Epub 2013 Aug 21.
Although EphA3 expression has been associated with progression or prognosis in several types of tumors, the role of EphA3 in hepatocellular carcinoma (HCC) remains unknown. This study sought to investigate the clinicopathological and prognostic relevance of EphA3 expression in HCC as well as the underlying mechanisms responsible. EphA3 protein was mainly localized within the cytoplasm and at the cell membrane. High EphA3 expression was correlated with tumor size, tumor grade, metastasis, venous invasion and AJCC TNM stage (P<0.05), and patients with high levels of EphA3 expression were at a significantly increased risk for shortened survival time (P<0.05). In vitro, the downregulation of EphA3 expression decreased the invasive capacity of HCC cells via the regulation of VEGF. EphA3 may represent a novel candidate marker for patient prognosis as well a molecular target for HCC therapy.
虽然 EphA3 的表达与多种类型肿瘤的进展或预后相关，但 EphA3 在肝细胞癌（HCC）中的作用尚不清楚。本研究旨在探讨 EphA3 表达在 HCC 中的临床病理和预后相关性及其相关机制。EphA3 蛋白主要定位于细胞质和细胞膜内。高 EphA3 表达与肿瘤大小、肿瘤分级、转移、静脉侵犯和 AJCC TNM 分期相关（P<0.05），并且 EphA3 高表达的患者生存时间明显缩短（P<0.05）。在体外，通过调节 VEGF，下调 EphA3 表达可降低 HCC 细胞的侵袭能力。EphA3 可能是患者预后的一个新的候选标志物，也是 HCC 治疗的一个分子靶点。
